ARQULE, INC.
Presenter SpeechPeter Lawrence (Executives)Good morning, everyone. Welcome to the ArQule inves...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.
| 1st Jan change | Capi. | |
|---|---|---|
| +21.74% | 46.81B | |
| -0.97% | 41.37B | |
| +47.07% | 41.29B | |
| -3.52% | 28.87B | |
| +11.12% | 26.06B | |
| -19.37% | 19.13B | |
| +31.18% | 12.39B | |
| -0.04% | 12.08B | |
| +0.39% | 11.96B |
